Conversion calendar in hand: management narrates the coming year as dated deliveries of business already secured
The model's full reasoning — Q4 2021 call → NOWe need to determine if management lays out a timetable of specific conversions that are already secured or in motion, with timing, and presents that as the forward story. Let's examine the transcript. Key points from management: - Rob Fried mentions new partnerships: Sinopharm, H&H Group, Ro, Designs for Health. He says "All of our new partnerships in various stages of product development, but we expect them to contribute to increased sales in 2022." That's vague. - Kevin Farr: "We expect more meaningful revenue contribution in aggregate from our new partners in 2021 and Designs for Health in early 2022." That's somewhat specific but not a detailed timetable. - On Sinopharm: "We're finalizing the commercial plans and the supply agreement Sinopharm for initial cross-border sales, as well as our approach to pursuing Blue Hat approval in parallel." That's still in finalization, not secured. - On H&H: "While our expectation is that H&H will not launch in the first quarter of 2022 as previously communicated, our R&D team continues to work closely with H&H on the new product formulation." So it's delayed, not yet launched. - On Nestle: "we are in discussions about how to make the partnerships more impactful over time." That's just discussions. - On new product launch: "we're launching a new Tru Niagen product this year... I'm excited to share more once it's in the market." No specific timing. - On TV campaign: "one of our new TV commercials begins very nationally in March." That's a marketing campaign, not a conversion of secured business. - On Walmart: "We shared this campaign with Walmart and they remain enthusiastic about us building the NAD+ categories together with them." That's not a specific secured item. - On Designs for Health: "Designs for Health will offer specifically formulated products with Niagen exclusively to these HCPs." But no timing given for when that starts contributing. - Kevin Farr: "We expect that selling and marketing expense will be down slightly as a percentage of net sales on a full year basis... We expect that R&D will be up approximately $2 million... We expect that reported G&A will be down $5 million to $6 million..." That's cost guidance, not revenue timetable. - For revenue guidance: "we expect around 15% to 20% growth year-over-year." But that's overall, not a schedule of specific items.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ESEA | Euroseas Ltd. | Q4 2022 | 2023-02-15 | C+ |
| SOL | ReneSola Ltd | Q3 2022 | 2022-12-01 | C+ |
| FLL | Full House Resorts, Inc. | Q3 2022 | 2022-11-07 | B |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| CPK | Chesapeake Utilities Corporation | Q3 2017 | 2017-11-10 | A |
| ESE | ESCO Technologies Inc. | Q2 2016 | 2016-05-03 | A |
CPK · Q3 2017 → YESThe question is about whether management lays out a timetable of specific conversions for the next four or so quarters, with already secured business and approximate time frames.
SOL · Q3 2022 → YESThe question is about whether management lays out a timetable of specific conversions for the next four or so quarters, with already secured items and approximate time frames.
FLL · Q3 2022 → YESThe question is about whether management lays out a timetable of specific conversions for the next four or so quarters, with already secured items and approximate time frames.